PHVS
Pharvaris NV
NASDAQ · Healthcare · Biotechnology · NL
$36.37
−4.29%0
Insider buys (3m)
25
Insider sells (3m)
-$11.3M
Net value (3m)
+11.8%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 17, 2026 | Abele Stefan Andreas · officer: Chief Technical Ops Officer | Sale | 45,000 | $38 |
| Sep 17, 2026 | Glassman Robert · director | M-Exempt | 8,667 | $22 |
| Sep 17, 2026 | Abele Stefan Andreas · officer: Chief Technical Ops Officer | Sale | 1,400 | $39 |
| Sep 17, 2026 | Abele Stefan Andreas · officer: Chief Technical Ops Officer | M-Exempt | 45,000 | $16 |
| Sep 17, 2026 | Glassman Robert · director | Sale | 8,667 | $38 |
| Sep 16, 2026 | Souverijns Wim · officer: Chief Commercial Officer | Sale | 6,090 | $39 |
| Sep 16, 2026 | Souverijns Wim · officer: Chief Commercial Officer | Sale | 20,000 | $39 |
| Sep 16, 2026 | Souverijns Wim · officer: Chief Commercial Officer | M-Exempt | 20,000 | $17 |
| Sep 15, 2026 | Lu Peng · officer: President | Sale | 15,000 | $40 |
| Sep 15, 2026 | Modig Berndt · director, officer: Chief Executive Officer | Sale | 2,291 | $39 |
| Sep 15, 2026 | Lu Peng · officer: President | F-InKind | 117 | $38 |
| Sep 15, 2026 | Lu Peng · officer: President | F-InKind | 109 | $38 |
| Sep 15, 2026 | Lu Peng · officer: President | M-Exempt | 15,000 | $2.59 |
| Sep 14, 2026 | Lesage Anne · officer: Chief Early Development | Sale | 30,000 | $38 |
| Sep 14, 2026 | Lesage Anne · officer: Chief Early Development | M-Exempt | 8,000 | $8.05 |
| Sep 14, 2026 | Lesage Anne · officer: Chief Early Development | M-Exempt | 30,000 | $8.05 |
| Sep 11, 2026 | Glassman Robert · director | Sale | 8,000 | $38 |
| Sep 11, 2026 | Glassman Robert · director | M-Exempt | 8,000 | $20 |
| Sep 9, 2026 | Lu Peng · officer: President | M-Exempt | 15,000 | $2.59 |
| Sep 9, 2026 | Lu Peng · officer: President | Sale | 15,000 | $41 |
| Aug 18, 2026 | Modig Berndt · director, officer: Chief Executive Officer | Sale | 2,292 | $35 |
| Aug 13, 2026 | Lu Peng · officer: President | F-InKind | 117 | $34 |
| Aug 13, 2026 | Lu Peng · officer: President | F-InKind | 109 | $35 |
| Jul 15, 2026 | Modig Berndt · director, officer: Chief Executive Officer | Sale | 2,292 | $35 |
| Jul 14, 2026 | Lu Peng · officer: Chief Medical Officer | F-InKind | 117 | $35 |
| Jul 14, 2026 | Lu Peng · officer: Chief Medical Officer | F-InKind | 109 | $35 |
| Jul 1, 2026 | Lesage Anne · officer: Chief Early Development | Sale | 6,997 | $35 |
| Jul 1, 2026 | Lesage Anne · officer: Chief Early Development | Sale | 27,872 | $35 |
| Jul 1, 2026 | Lesage Anne · officer: Chief Early Development | M-Exempt | 24,900 | $8.05 |
| Jul 1, 2026 | Lesage Anne · officer: Chief Early Development | M-Exempt | 2,972 | $2.59 |
Institutional positioning
13F filings over the trailing two quarters
New 34Increased 84Reduced 70Sold out 9
| Filer | Action | Shares | Filed |
|---|---|---|---|
| GENERAL ATLANTIC, L.P. | Unchanged | 8,031,252 | May 15, 2026 |
| FMR LLC | Increased | 6,565,272 | Aug 13, 2026 |
| GENERAL ATLANTIC, L.P. | Reduced | 6,550,757 | Aug 14, 2026 |
| FMR LLC | Reduced | 6,284,472 | May 15, 2026 |
| Foresite Capital Management IV, LLC | Unchanged | 4,778,581 | Aug 14, 2026 |
| FORESITE CAPITAL MANAGEMENT IV, LLC | Unchanged | 4,778,581 | May 15, 2026 |
| venBio Partners LLC | Increased | 4,643,430 | Aug 14, 2026 |
| VENBIO PARTNERS LLC | Unchanged | 4,639,304 | May 15, 2026 |
| VIKING GLOBAL INVESTORS LP | Unchanged | 3,653,310 | May 15, 2026 |
| VIKING GLOBAL INVESTORS LP | Unchanged | 3,653,310 | Aug 14, 2026 |
| EQT Fund Management S.a r.l. | Unchanged | 3,424,609 | Aug 13, 2026 |
| EQT FUND MANAGEMENT S.A R.L. | Unchanged | 3,424,609 | May 14, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | Increased | 3,376,042 | Aug 14, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Unchanged | 3,126,042 | May 15, 2026 |
| Bain Capital Life Sciences Investors, LLC | Unchanged | 2,675,509 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 17, 2026